Skip to content
lifestyle.thepointnews.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Plus Therapeutics Inc.
Plus Therapeutics Announces CAP Accreditation of CNSide® Diagnostics Clinical Laboratory
June 4, 2026
Plus’ CNSide Diagnostic Platform Demonstrates Substantial Healthcare Cost Reduction in Patients with Leptomeningeal Metastases
May 26, 2026
Plus Therapeutics Partners with Ephemeral Technologies to Deploy AI Execution Platform for CNS Oncology
May 19, 2026
Plus Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update on REYOBIQ™ Clinical Program and CNSide® Commercial Rollout
May 15, 2026
Plus Therapeutics Announces Oral Presentation Highlighting REYOBIQ™ Clinical and Translational Data Demonstrating Favorable Safety, Survival, and Emerging Immunomodulation in Leptomeningeal Metastases
May 8, 2026
Plus Therapeutics Receives Medicare Enrollment Approval for CNSide Diagnostic
May 7, 2026
Plus Therapeutics Secures Blue Shield of California Coverage for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
April 28, 2026
Plus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ™
April 23, 2026
Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
April 22, 2026
Plus Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
April 21, 2026
1
2
3
Next Page
→